PCSK9 inhibitor
AstraZeneca’s oral PCSK9 inhibitor halves cholesterol in phase 2 trial
AZD0780, LDL Cholesterol Lipoproteins, AstraZeneca ‘s, Oral cavity, PCSK9 inhibitor, Effectiveness
Actionable Insights Powered by AI
AZD0780, LDL Cholesterol Lipoproteins, AstraZeneca ‘s, Oral cavity, PCSK9 inhibitor, Effectiveness